Bayer: 5 new Phase III drugs expected in 2015

Share this article:

Bayer said Tuesday that it is accelerating its pipeline and expects to have five drugs in Phase III testing in 2015. The drug maker said in a statement that the drugs will swell its oncology, cardiology and women's health list of experimental treatments.

This is in addition to working on expanding the list of indications for drugs including heart drug Xarelto, cancer medication Xofigo and eye treatment Eylea.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

India's Marck gets FDA Warning Letter

Inspectors of Marck Biosciences found an array of problems during a October-November 2013 inspection, including mold near a sterile area that was so bad "the room had 'partially caved in.'"

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.